Dr. Wamhoff serves as HemoShear Therapeutics' Head of Innovation and is a company founder. He is responsible for development and management of strategic team initiatives to ensure a robust pipeline of disease models to advance our drug discovery platform and early stage therapeutic programs. Dr. Wamhoff has led teams to oversee the successful development of human vascular and liver disease models, as well as ongoing development of a tumor microenvironment system. These advancements have been built in part by his role in securing significant NIH Small Business Innovation Research funding from five different NIH institutes. Additional activities include scientific publication strategy and activities, thought leader development and engagement activities, and intellectual property and patent strategy. Dr. Wamhoff, former Associate Professor at the University of Virginia, has co-founded multiple medical device and therapeutics companies. He obtained a B.S. in biology with a minor in business administration from Rhodes College, where he was the 2011 Distinguished Alumnus; he received his Ph.D. in medical physiology from the University of Missouri.
Richard White is a CPA and tax professional and serves as the vice president of finance for HemoShear Therapeutics. Mr. White directs our financial, tax, and accounting activities. He founded his own tax and accounting firm in Charlottesville before joining HemoShear. Mr. White holds B.S. degrees in accounting and organizational behavior management from the University of Virginia.
John E. Reardon is the acting Head of Research and Development for HemoShear Therapeutics. Prior to joining HemoShear in 2016, Dr. Reardon was the Chief Scientific Officer at Cardioxyl Pharmaceuticals, Inc where he successfully led development of a heart failure therapeutic in to Phase II, which was acquired by Bristol-Meyers Squibb in 2015 in a potential $2B deal. Before joining Cardioxyl, Dr. Reardon was Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions, Inc. from 2007 – 2009. Dr. Reardon spent 19 years at GlaxoSmithKline PLC and its predecessor companies where he held a variety of leadership positions. As Senior Vice President of Discovery Research Biology at GlaxoSmithKline he oversaw the biological science supporting lead discovery activities across all the therapeutic areas in the international GSK R&D organization. Dr. Reardon received a B.A. from Willamette University, Oregon and a PhD degree in Chemistry from The Ohio State University, Ohio. He was an NIH post-doctoral fellow in the laboratory of Dr. Robert Abeles at Brandeis University before joining Burroughs-Wellcome Co. in 1986.
Board of Directors
John L. Brooks, III, is the CEO of Arete Worldwide, LLC in Boston. He was previously the President and CEO of the Joslin Diabetes Center. He serves on the boards of Pathfinder Cell Therapy, Noxilizer, Ammonett Pharma, Longwood Energy Collaborative, Reflectance Medical, Inc., Suffolk University and Thermalin Diabetes. He was a founding partner of Prism Ventureworks. Prism has raised more than $1.25 billion and is based in Needham, MA. Mr. Brooks was formerly a general manager at Pfizer/Valleylab in Boulder, CO, where he developed and executed a minimally invasive surgery and emerging businesses strategy. Prior to Valleylab, he led the growth of a rapidly evolving vascular access medical device business at Pfizer/Strato Medical. Mr. Brooks has co-founded three paradigm-shifting life sciences companies: Songbird Hearing, Locus Pharmaceuticals and Insulet (PODD). He is a biotechnology advisory board member for Draper Labs. In addition, Mr. Brooks is a member of M2D2, an early-stage medical technology accelerator and a board member of the Massachusetts Technology Transfer Center (MTTC) advisory boards. He holds an MS in business and a BBA cum laude from the University of Massachusetts at Amherst. He is a certified public accountant and a certified financial planner.
H. Thomas Watkins is former Director, President, and CEO of Human Genome Sciences (HGS) from 2004 until HGS was acquired by GlaxoSmithKline in 2012. During his tenure, HGS successfully developed and brought Benlysta to market in 2011, the first new lupus drug to be introduced in 50 years. Prior to HGS, Mr. Watkins spent over 20 years in senior roles at Abbott and its affiliates in the U.S. and Asia. He was President of TAP Pharmaceutical Products, Inc., which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc., where he led the growth of TAP from approximately $2 billion to over $4 billion in annual revenue. Previously, Mr. Watkins was a consultant with McKinsey and Company and Arthur Andersen. He is former Chairman of the Biotechnology Industry Organization (BIO) and continues to serve on its board. He is currently Chairman of the board of directors of Vanda Pharmaceuticals, Inc., and Vice Rector of the Board of Visitors of The College of William and Mary. Mr. Watkins received a B.B.A. in accounting from the College of William and Mary and his M.B.A. from the University of Chicago Graduate School of Business, now the Booth School of Business.
Robert J. Gould, Ph.D. is former President, Chief Executive Officer and current board member of Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients. He has held this position since March 2010, serving on the board of Epizyme from 2008 - 2010. Prior to joining Epizyme in March 2010, Dr. Gould was Director of Novel Therapeutics from 2007 - 2010 at The Broad Institute of MIT and Harvard. Dr. Gould spent 23 years at Merck & Co., Inc., a healthcare company, where he held a variety of leadership positions during his tenure there. As Vice President, Basic Research, he oversaw drug discovery activities for seven therapeutic areas, as well as Merck’s centralized high throughput screening facility. In addition, he spent three years as Vice President, Licensing and External Research. Dr. Gould received a B.A. in chemistry from Spring Arbor College, Michigan and a Ph.D. in biochemistry from The University of Iowa, Iowa. He also conducted post-doctoral studies in neuropharmacology at The Johns Hopkins University before joining Merck & Co., in 1981.
Mehmood Khan, MD, is the Vice Chairman of PepsiCo, Inc., where he is responsible for leading all aspects of the company’s research and development and product and equipment strategy. He provides global leadership and support to division research and development groups in the areas of enterprise research planning, R&D portfolio management, next generation technologies, nutritional standards, food safety and regulation and quality assurance. Prior to joining PepsiCo in 2007, Dr. Khan served as president of Takeda Global Research & Development Center, Inc. (TGRD). Dr. Khan has also served as consultant physician in Endocrinology and Director of the Diabetes, Endocrine and Nutrition Clinical Trials Unit in the Division of Endocrinology at the Mayo Clinic in Rochester, Minn.
Dr. Khan earned his MD from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a member of the Royal College of Physicians, London and a fellow of the American College of Endocrinology.
Reginald F. Woods was CEO of Butler International where he led a successful corporate turnaround that became the subject of three Harvard Business School case studies. The Butler companies generated significant earnings expansion through organic growth and acquisitions in their respective industries. Butler International was listed on the NYSE and was later acquired by a financial buyer at an attractive valuation. Mr. Woods then co-founded a merger and acquisition consulting practice specializing in the insurance industry. He is a founding Director of HemoShear Therapeutics, LLC, a founding Director and Chairman of Dynamic Literacy, LLC, and a Director of Scitent, Inc. He is on the Advisory Board of the University of Virginia Heart and Vascular Center, was co-founder of the Keswick Community Foundation, and has served on the board and executive committee of Habitat for Humanity of Greater Charlottesville. He earned B.S. and M.S. degrees in engineering and an M.B.A. from Cornell University.
W. McIlwaine (Mac) Thompson, Jr. is of counsel to the law firm of Woods Rogers PLC and specializes in representing companies in many diverse fields including biotechnology, information technology and oil and gas exploration. Mr. Thompson is secretary of Insmed Incorporated, a publicly traded biotechnology company, and is a member of the boards of Mestena Inc., an oil- and gas-exploration company, and Foundation Energy Management, LLC, which acquires oil- and gas-producing properties. He is a member of the investment advisory board of Tall Oaks Capital, a venture capital fund based in Charlottesville, and has represented many biotechnology companies in the Charlottesville area. He is also a member of the advisory board for the University of Virginia’s Heart and Vascular Center and general counsel to, and immediate past chair of, the board of the U.Va. Curry School of Education Foundation. Mr. Thompson graduated from Yale College in 1969 and the U.Va. Law School in 1972.
Marshall L. Summar, MD, is Chief of the Division of Genetics and Metabolism and the Margaret O’Malley Chair of Molecular Genetics at Children’s National Medical Center. Dr. Summar is an international expert in inborn errors of metabolism particularly those in the urea cycle. His research involves translational studies taking basic molecular genetics research and developing direct clinical applications. He also is the Director for the NIH sponsored Clinical Research Center at Children’s National. His work has piloted treatments from the rare disease field to common conditions especially in the intensive care and emergency room setting. His work in the urea cycle has involved the development of treatment protocols, translational research, and basic molecular research into these rare defects in nitrogen and urea metabolism. He is one of the founding Investigators of the Urea Cycle Disorders Consortium and works with international coordination of its efforts. Current research projects involve clinical trials working to improve the outcomes of patients with congenital heart defects, acute lung injury, asthma, and premature infants using compounds from metabolic pathways he studies. He is also involved in device development around biochemical detection.
He serves on the board of the National Organization of Rare Diseases and Chairs its Scientific Advisory Committee and is the president-elect for the Society of Inherited Metabolic Disease. He serves on the NIH study section for the CETT program, the National Human Genetic Research Institute Fellowship Training Program Board, and the NASA radiation research review panel. He is the advisor for the European Inherited Metabolic Disease Consortium and on the working group for joint US-EU research in rare disease.
Dr. Arun Sanyal, is the Charles Caravati Professor and chair of the Division of Gastroenterology, Hepatology and Nutrition, in the Department of Internal Medicine at Virginia Commonwealth University. Dr. Sanyal currently leads an FDA committee working on defining clinical endpoints and regulatory approval criteria for NASH and is similarly working with the European Medicines Agency. He is also Chairman of the NIH NASH Research Network, serves as principal investigator for a number of NASH clinical studies, and consults for a number of pharma companies that are in later stages of NASH drug development.
Dr. Hayes has more than 25 years of experience in research and development of protein therapeutics. Through the end of 2015, he was Senior Vice President of Regulatory Affairs and Pharmacovigilance at Synageva Biopharma prior to their acquisition by Alexion Pharmaceuticals, where he led efforts to support the approval of Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency, a rare genetic lipid metabolic disorder affecting children and adults, and provided strategic regulatory leadership for additional pipeline products for other serious and life-threatening rare genetic diseases affecting predominantly pediatric patients. Prior to Synageva, Dr. Hayes was Group Vice President of Regulatory Affairs at Genzyme Corporation and he served at FDA for over 9 years in the Center for Biologics Evaluation and Research, Division of Therapeutic Proteins. Dr. Hayes received a BS from Davidson College and holds a PhD in Immunology and Experimental Pathology from the University of Florida. He completed post-doctoral fellowship at the National Cancer Institute in Bethesda, MD before joining FDA.
Dr. Bower is president of BRG LLC, a global market access consultancy dedicated to helping biotech and pharma organizations grow and become commercially successful. He held commercial and global market access leadership positions at Synageva, Amgen, ALZA and SmithKline Beecham. Before starting his own company in 2016, he was Vice President (Head) of Global Pricing, Reimbursement and Health Economics at Synageva BioPharma, which was acquired in 2015 by Alexion. In this capacity, reporting to the COO and to the Board, Dr. Bower was the lead executive responsible for payer relationships globally, and conceived of, supervised, and wrote parts of the global value dossier for Kanuma, which was Synageva’s first commercial product. Prior to that, he headed pricing and contracting for the $3B International operation at Amgen, while based near Zurich. In addition to over a dozen years of experience in industry and several years in consulting, he spent a decade at RAND, where he held the position of Senior Economist and published on health economics and technology assessments, as well as on the diffusion of information technology in health care.
John L. LaMattina, PhD, is the former senior vice president, Pfizer Inc. and president of Pfizer global research and development. In this role, Dr. LaMattina supervised the drug discovery and development efforts of more than 12,000 colleagues in the United States, Europe and Asia. During his tenure, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS. He retired from this position in December 2007. He is currently a senior partner at PureTech Ventures and also serves on the board of directors of Human Genome Sciences, the board of directors of Ligand Pharmaceuticals, the scientific advisory board of Trevena and the board of trustees of Boston College, where he chairs the Academic Affairs Committee.
Dr. LaMattina attended the University of New Hampshire working with Professor Robert E. Lyle and received a PhD from UNH in organic chemistry. He graduated cum laude from Boston College with a BS in chemistry. He is the author of numerous scientific publications and holds a number of U.S. patents. Dr. LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, an Honorary Doctor of Science degree from the University of New Hampshire in 2007, and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management.
Mr. Scheer serves as President of Scheer & Company, Inc., providing venture capital, corporate strategic and transactional advisory services in the life sciences industry. He was a cofounder, and serves as the Chairman of the Board of Directors of Achillion Pharmaceuticals, Inc. Mr. Scheer also serves on the Board of Aegerion Pharmaceuticals, Inc., and as Chairman of the Board of Directors of several privately held biotechnology companies. He was involved in the founding and was on the Boards of a series of other privately- and publicly-held companies, including Viropharma, Inc. (acquired by Shire), OraPharma (acquired by JNJ), Esperion Therapeutics (acquired by Pfizer), and Tengion. Additionally, Mr. Scheer serves as a member of the Board of Directors of Connecticut United for Research Excellence (CURE), an educational and business advocacy network, and on the Executive Board of the Center for Biomedical Interventional Technologies (CBIT) at Yale University. He has been a co-organizer and/or Chair of a series of life science conferences involving public and global health in collaboration with Yale, and has been a co-organizer, and speaker at a series of annual conferences involving orphan drug innovation for the National Organization for Rare Disorders. Mr. Scheer holds an AB degree in Biochemical Sciences from Harvard College and an MS degree in Cell, Molecular and Developmental Biology from Yale University.